[Hypotensive therapy and the level of blood lipids in patients with chronic nephritis associated with arterial hypertension]. 1989

N I Neverov, and R I Kozlova, and I V Vinogradova, and G M Galstian, and O B Shatskaia

A study was made of the content of blood lipids in patients with associated chronic nephritis and arterial hypertension (AH). It has been established that the reduction of arterial pressure as a result of hypotensive therapy (administration of central action drugs, vasodilators of direct action, calcium antagonists, blockers of the angiotensin-transforming enzyme) was followed by a decrease in the blood of the concentration of fatty acids, glycerin, triglycerides, low density lipoproteins, total cholesterol, free cholesterol, phospholipids, characteristics of lipid peroxidation and by the rise of cholesterol concentration in high density lipoproteins. The data obtained are of clinical importance in view of the possibility of correcting dyslipidemia in patients with associated chronic nephritis and arterial hypertension during hypotensive treatment.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008055 Lipids A generic term for fats and lipoids, the alcohol-ether-soluble constituents of protoplasm, which are insoluble in water. They comprise the fats, fatty oils, essential oils, waxes, phospholipids, glycolipids, sulfolipids, aminolipids, chromolipids (lipochromes), and fatty acids. (Grant & Hackh's Chemical Dictionary, 5th ed) Lipid
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D005260 Female Females
D005921 Glomerulonephritis Inflammation of the renal glomeruli (KIDNEY GLOMERULUS) that can be classified by the type of glomerular injuries including antibody deposition, complement activation, cellular proliferation, and glomerulosclerosis. These structural and functional abnormalities usually lead to HEMATURIA; PROTEINURIA; HYPERTENSION; and RENAL INSUFFICIENCY. Bright Disease,Kidney Scarring,Glomerulonephritides,Scarring, Kidney
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000806 Angiotensin-Converting Enzyme Inhibitors A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. ACE Inhibitor,ACE Inhibitors,Angiotensin Converting Enzyme Inhibitor,Angiotensin I-Converting Enzyme Inhibitor,Angiotensin-Converting Enzyme Inhibitor,Kininase II Inhibitor,Kininase II Inhibitors,Angiotensin I-Converting Enzyme Inhibitors,Angiotensin-Converting Enzyme Antagonists,Antagonists, Angiotensin-Converting Enzyme,Antagonists, Kininase II,Inhibitors, ACE,Inhibitors, Angiotensin-Converting Enzyme,Inhibitors, Kininase II,Kininase II Antagonists,Angiotensin Converting Enzyme Antagonists,Angiotensin Converting Enzyme Inhibitors,Angiotensin I Converting Enzyme Inhibitor,Angiotensin I Converting Enzyme Inhibitors,Antagonists, Angiotensin Converting Enzyme,Enzyme Antagonists, Angiotensin-Converting,Enzyme Inhibitor, Angiotensin-Converting,Enzyme Inhibitors, Angiotensin-Converting,II Inhibitor, Kininase,Inhibitor, ACE,Inhibitor, Angiotensin-Converting Enzyme,Inhibitor, Kininase II,Inhibitors, Angiotensin Converting Enzyme

Related Publications

N I Neverov, and R I Kozlova, and I V Vinogradova, and G M Galstian, and O B Shatskaia
April 1985, Polski tygodnik lekarski (Warsaw, Poland : 1960),
N I Neverov, and R I Kozlova, and I V Vinogradova, and G M Galstian, and O B Shatskaia
January 2009, Kardiologiia,
N I Neverov, and R I Kozlova, and I V Vinogradova, and G M Galstian, and O B Shatskaia
December 1988, Kardiologiia,
N I Neverov, and R I Kozlova, and I V Vinogradova, and G M Galstian, and O B Shatskaia
January 1961, British medical journal,
N I Neverov, and R I Kozlova, and I V Vinogradova, and G M Galstian, and O B Shatskaia
January 1955, Archivos. Hospital Universitario General Calixto Garcia,
N I Neverov, and R I Kozlova, and I V Vinogradova, and G M Galstian, and O B Shatskaia
February 2020, European cardiology,
N I Neverov, and R I Kozlova, and I V Vinogradova, and G M Galstian, and O B Shatskaia
May 1975, Vrachebnoe delo,
N I Neverov, and R I Kozlova, and I V Vinogradova, and G M Galstian, and O B Shatskaia
January 1983, Medicina,
N I Neverov, and R I Kozlova, and I V Vinogradova, and G M Galstian, and O B Shatskaia
January 1987, Terapevticheskii arkhiv,
N I Neverov, and R I Kozlova, and I V Vinogradova, and G M Galstian, and O B Shatskaia
April 1988, Casopis lekaru ceskych,
Copied contents to your clipboard!